Sign Up Now

CONTACT ME to sign up for a study

Our Location

(click on Image for map)
7420 Central
Ste 2020
River Forest, Il  60305

Contact Us

Asthma and Allergy Center
 of Chicago, SC
7420 Central
River Forest, Il 60305
708-366-9300
info@research4health.com

Cindy Rutherford, CCRC
Clinical Trials Manager
cindy.rutherford@att.net

Noemi Mendoza, CCRC
Asst Trials Manager
na.mendoza@att.net

Note: Please don't send us any specific information about your history via email.  Despite our best assurances we don't believe that email is ever 100% confidential

Free Transportation

If you are over 60, ask about free transpor-tation to and from home to the Center for your research study visits

EMAIL ME !

Want us to contact you about what's going on? Just click on SUBSCRIBE, enter your first/last name in the email body...and we'll take care of the rest

Welcome

Research4Health.Com
Information About Clinical Research in COPD, Asthma, and Allergic Disease
Asthma and Allergy Center of Chicago, SC
Leading Chicago in Community Based Asthma, COPD & Allergic Disease Clinical Research

Have You Talked to Someone About Clinical Research Today?

Hi, I'm Cindy, the Clinical Trials Manager at the Center.  Let me tell you a few things to help you navigate about this site.  At the top of every page, there are tabs which will help you get around.  First, I really encourage you to check out Our Mission, About Us, and Code of Conduct.  These pages will help give you a good idea about what distinguishes us from other hospitals and clinics which also conduct clinical research.

If you want to know what studies for which we are actively participants, check out the table below or click on Find A Research Study.  Interested in joining a study, first check out Questions You Need to Ask ; it has very important information that anyone considering participation in clinical research at any site should be aware.

Do you have a question for us?  You can use Sign-Up for A Study or email us at info@research4health.com.  We'll get back to you with an answer as soon as possible. 

Keep up with what's going on here at the Center at WHAT'S NEW: Asthma, Allergy & COPD. Want links to various websites with information regarding diagnosis, treatment, and management of Asthma, COPD, and Allergic disease?... visit Asthma & COPD Research Info .  You'll also find links to the FDA, the national registry for clinical trials, and other info at Asthma & COPD Research Links .

Need a map to find us?  Our Location will take you to us, or click on the image on the top left side bare (under Our Location) for a map to our site.

One more thing, please help us get the word out about the opportunity to participate in COPD, Asthma, and Allergic disease clinical research here at the Asthma and Allergy Center of Chicago.  You can download flyers and ads at Ads-Flyers to post at your office and freely distribute anywhere you'd like....thanks! Have any more questions?  Feel free to CONTACT US .

 DISEASE 
STUDY
 COMMENTS

Asthma		 A phase IIb, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and dosing regimens of MEMP1972A in adults with allergic asthma who are inadequately controlled on inhaled corticosteroids and a second controller (COSTA) 
 

Male / Female Ages 18 - 75
   

 Asthma		 A randomized, placebo-controlled, dose-ranging, multicentre trial of QAW039 (1-450 mg p.o.) to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy

 Male / Female Ages 18 - 75
   

Cat Allergies
 A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide  Immunotherapy in Cat Allergic SubjectsMust live in Home with a Cat
Male /Female ages 18-65
   

 COPD		 A 12-week multi-center, randomized, double-blind, placebo controlled study to assess the efficacy and safety of NVA237 in stable COPD patients 
Male / Female Ages > 40
   

 COPD		 A randomised, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5ug (delivered by Respimat Inhaler) and tiotropium 18 ug (delivered by the HandiHaler) compared to once daily, orally inhaled, co-administration of placebo (delivered by Respimat Inhaler) and tiotropium 18 ug (delivered by the HandiHaler) in patients with Chronic Obstructive Pulmonary Disease (COPD)


Male / Female Ages > 40
   

 COPD		 A 12-week treatment, multi-center, randomized, double-blind, parallel-group, placebo and active controlled study to assess the effecacy, safety, and tolerability of QVA149 (indacaterol maleate / glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation
 Male / Female Ages > 40
   

 COPD		 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/23mcg with placebo on Survival in Subjects with moderate COPD and a history of or at increased risk for cardiovascular disease
 Male / Female Ages > 40
   

VISIT US AT: